Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
CSET 2023/3603
Phase 3 small_molecule active
Quick answer
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets for Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active